Convalescent Plasma Transfusion In Severe Covid-19 Patients Admitted To Intensive Care Unit: A Single Center Study

Cokorda Agung Wahyu Purnamasidhi; Ida Bagus Yorky Brahmantya; Ni Made Dewi Dian Sukmawati; Anak Agung Ayu Yuli Gayatri; I Made Susila Utama; I Ketut Agus Somia; I Gusti Ngurah Mahaalit Aribawa; Ketut Tuti Parwati Merati

Makale detayları

Convalescent Plasma Transfusion In Severe Covid-19 Patients Admitted To Intensive Care Unit: A Single Center Study

Yazarlar:

Cokorda Agung Wahyu Purnamasidhi | Ida Bagus Yorky Brahmantya | Ni Made Dewi Dian Sukmawati | Anak Agung Ayu Yuli Gayatri | I Made Susila Utama | I Ketut Agus Somia | I Gusti Ngurah Mahaalit Aribawa | Ketut Tuti Parwati Merati

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Health Care Administration

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 2, pp.258-263

Belge Tipi:

Makale

Yayın Tarihi:

7/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001293707

pISSN:

1309-4483

Anahtar kelimeler:

Özet:

 Initial difficult times of novel coronavirus disease 2019 COVID-19 had clinicians actively seeking appropriate treatment. Convalescent plasma CP has been studied for treatment of past coronavirus pandemics and was successful with promising efficacy and safety. This study aims to measure the efficacy of convalescent plasma transfusion in severe COVID-19 patients, determined by alleviation of symptoms, improvement in radiologic findings, and laboratory parameters. Cross-sectional study conducted involving 23 severe COVID-19 patients admitted to Udayana University Hospital intensive care unit in 2020. Patients received a minimum 200 mL CP transfusion, dexamethasone, and remdesivir. Data were retrieved from patients medical records. Patients mean age was 54.04 years. Mean time from onset of illness to transfusion and length of stay were 11.09 and 16.70 days respectively. No adverse effects were observed during treatment. Twelve patients 52.2 showed alleviation of symptoms and recovered, with 15 days median time from transfusion to recovery. Post-transfusion chest x-ray examination showed varying degrees of absorption of lung lesions in 10 patients 43.5 and was associated with the patients outcome p  0.001. Significant changes in c-reactive protein p  0.000 and procalcitonin level p  0.024 was found as compared to pretransfusion. Despite these findings, almost half the patients 47.8 did not receive benefits from CP transfusion and dead. CP transfusion has shown remarkable improvement in radiologic, inflammatory, and prognostic parameters but was unable to improve patient clinical outcomes and mortality rate.

 Initial difficult times of novel coronavirus disease 2019 COVID-19 had clinicians actively seeking appropriate treatment. Convalescent plasma CP has been studied for treatment of past coronavirus pandemics and was successful with promising efficacy and safety. This study aims to measure the efficacy of convalescent plasma transfusion in severe COVID-19 patients, determined by alleviation of symptoms, improvement in radiologic findings, and laboratory parameters. Cross-sectional study conducted involving 23 severe COVID-19 patients admitted to Udayana University Hospital intensive care unit in 2020. Patients received a minimum 200 mL CP transfusion, dexamethasone, and remdesivir. Data were retrieved from patients medical records. Patients mean age was 54.04 years. Mean time from onset of illness to transfusion and length of stay were 11.09 and 16.70 days respectively. No adverse effects were observed during treatment. Twelve patients 52.2 showed alleviation of symptoms and recovered, with 15 days median time from transfusion to recovery. Post-transfusion chest x-ray examination showed varying degrees of absorption of lung lesions in 10 patients 43.5 and was associated with the patients outcome p  0.001. Significant changes in c-reactive protein p  0.000 and procalcitonin level p  0.024 was found as compared to pretransfusion. Despite these findings, almost half the patients 47.8 did not receive benefits from CP transfusion and dead. CP transfusion has shown remarkable improvement in radiologic, inflammatory, and prognostic parameters but was unable to improve patient clinical outcomes and mortality rate.

 Initial difficult times of novel coronavirus disease 2019 COVID-19 had clinicians actively seeking appropriate treatment. Convalescent plasma CP has been studied for treatment of past coronavirus pandemics and was successful with promising efficacy and safety. This study aims to measure the efficacy of convalescent plasma transfusion in severe COVID-19 patients, determined by alleviation of symptoms, improvement in radiologic findings, and laboratory parameters. Cross-sectional study conducted involving 23 severe COVID-19 patients admitted to Udayana University Hospital intensive care unit in 2020. Patients received a minimum 200 mL CP transfusion, dexamethasone, and remdesivir. Data were retrieved from patients medical records. Patients mean age was 54.04 years. Mean time from onset of illness to transfusion and length of stay were 11.09 and 16.70 days respectively. No adverse effects were observed during treatment. Twelve patients 52.2 showed alleviation of symptoms and recovered, with 15 days median time from transfusion to recovery. Post-transfusion chest x-ray examination showed varying degrees of absorption of lung lesions in 10 patients 43.5 and was associated with the patients outcome p  0.001. Significant changes in c-reactive protein p  0.000 and procalcitonin level p  0.024 was found as compared to pretransfusion. Despite these findings, almost half the patients 47.8 did not receive benefits from CP transfusion and dead. CP transfusion has shown remarkable improvement in radiologic, inflammatory, and prognostic parameters but was unable to improve patient clinical outcomes and mortality rate.

 Initial difficult times of novel coronavirus disease 2019 COVID-19 had clinicians actively seeking appropriate treatment. Convalescent plasma CP has been studied for treatment of past coronavirus pandemics and was successful with promising efficacy and safety. This study aims to measure the efficacy of convalescent plasma transfusion in severe COVID-19 patients, determined by alleviation of symptoms, improvement in radiologic findings, and laboratory parameters. Cross-sectional study conducted involving 23 severe COVID-19 patients admitted to Udayana University Hospital intensive care unit in 2020. Patients received a minimum 200 mL CP transfusion, dexamethasone, and remdesivir. Data were retrieved from patients medical records. Patients mean age was 54.04 years. Mean time from onset of illness to transfusion and length of stay were 11.09 and 16.70 days respectively. No adverse effects were observed during treatment. Twelve patients 52.2 showed alleviation of symptoms and recovered, with 15 days median time from transfusion to recovery. Post-transfusion chest x-ray examination showed varying degrees of absorption of lung lesions in 10 patients 43.5 and was associated with the patients outcome p  0.001. Significant changes in c-reactive protein p  0.000 and procalcitonin level p  0.024 was found as compared to pretransfusion. Despite these findings, almost half the patients 47.8 did not receive benefits from CP transfusion and dead. CP transfusion has shown remarkable improvement in radiologic, inflammatory, and prognostic parameters but was unable to improve patient clinical outcomes and mortality rate.

Makale detayları

Convalescent Plasma Transfusion In Severe Covid-19 Patients Admitted To Intensive Care Unit: A Single Center Study

Yazarlar:

Cokorda Agung Wahyu Purnamasidhi | Ida Bagus Yorky Brahmantya | Ni Made Dewi Dian Sukmawati | Anak Agung Ayu Yuli Gayatri | I Made Susila Utama | I Ketut Agus Somia | I Gusti Ngurah Mahaalit Aribawa | Ketut Tuti Parwati Merati

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Health Care Administration

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 2, pp.258-263

Belge Tipi:

Makale

Yayın Tarihi:

7/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001293707

pISSN:

1309-4483

convalescent plasma therapy

COVID-19

critical care

outcome

Sayı

Makale detayları

Convalescent Plasma Transfusion In Severe Covid-19 Patients Admitted To Intensive Care Unit: A Single Center Study

Yazarlar: Cokorda Agung Wahyu Purnamasidhi | Ida Bagus Yorky Brahmantya | Ni Made Dewi Dian Sukmawati | Anak Agung Ayu Yuli Gayatri | I Made Susila Utama | I Ketut Agus Somia | I Gusti Ngurah Mahaalit Aribawa | Ketut Tuti Parwati Merati

Yayıncı: Ondokuz Mayıs University

Ana Başlıklar: Health Care Administration

Dergi: Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 2, pp.258-263

Belge Tipi: Makale

Yayın Tarihi: 7/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001293707

pISSN: 1309-4483

convalescent plasma therapy

COVID-19

critical care

outcome

Sayı

Yazarlar:

Cokorda Agung Wahyu Purnamasidhi | Ida Bagus Yorky Brahmantya | Ni Made Dewi Dian Sukmawati | Anak Agung Ayu Yuli Gayatri | I Made Susila Utama | I Ketut Agus Somia | I Gusti Ngurah Mahaalit Aribawa | Ketut Tuti Parwati Merati

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Health Care Administration

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 2, pp.258-263

Belge Tipi:

Makale

Yayın Tarihi:

7/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001293707

pISSN:

1309-4483